Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Medulloblastoma 1High Grade Cervical Intraepithelial Neoplasia 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 5Trastuzumab 4Taxes 4Docetaxel 4Paclitaxel 3Albumin-Bound Paclitaxel 3tipifarnib 2sargramostim 2liposomal doxorubicin 2Vorinostat 2Immunohistochemistry 2Granulocyte-Macrophage Colony-Stimulating Factor 2Filgrastim 2Enzyme-Linked Immunosorbent Assay 2Doxorubicin 2Capecitabine 2temsirolimus 1seviteronel 1romidepsin 1poly(I).poly(c12,U) 1pertuzumab 1pegfilgrastim 1oblimersen 1ixabepilone 1interferon gamma-1b 1flt3 ligand protein 1denileukin diftitox 1cixutumumab 1alvocidib 1Vaccines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Breast Neoplasms, Male × Vaccines × Clear all
NCT01042535 2018-04-11

Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
44 enrolled 10 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡